CRNX
NASDAQCrinetics Pharmaceuticals Inc.
Price$35.02+0.72 (+2.10%)
01:30 PM07:45 PM
News · 26 weeks61-56%
2025-12-142026-06-07
Mix2690d
- SEC Filings8(31%)
- Other8(31%)
- Insider6(23%)
- Earnings2(8%)
- Leadership2(8%)
Latest news
25 items- PRCrinetics and Leading Patient Groups Launch 'Everyday Advocacy' Initiative to Empower People Across Endocrine Disease CommunitiesEveryday Advocacy provides people living with endocrine and endocrine-related conditions with education, support, and tools to facilitate more impactful healthcare team interactions Steering committee of five leading patient organizations to guide program with authentic perspectives and insights into most significant patient needs SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the launch of Everyday Advocacy, a new initiative designed to support patient education, self-advocacy, and connection within endocrine disease communities. "Crinetics is led by a conviction that meaningful progress for endocrine disease treatment begins
- INSIDERPresident & CEO Struthers Richard Scott gifted 968,800 shares and received a gift of 968,800 shares (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- PRCrinetics' Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six PresentationsOral presentation features open label extension PALSONIFY™ (paltusotine) data, reinforcing its best-in-class potential in acromegaly following recent U.S. and E.U. approvals Two oral presentations of novel, investigational ACTH receptor antagonist atumelnant include full Phase 2 study results in congenital adrenal hyperplasia and data from additional patients in the Phase 1b/2a ACTH-dependent Cushing's syndrome study SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that data from six abstracts, including oral presentations featuring PALSONIFY™ (paltusotine) and investigational candidate atumelnant, will be presented at t
- PRCrinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026SAN DIEGO, May 22, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 2-4, 2026 in New York, NY. Management will be available for 1x1 meetings with investors on Wednesday, June 3, 2026. If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on dis
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- SECSEC Form 10-Q filed by Crinetics Pharmaceuticals Inc.10-Q - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRCrinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdatePALSONIFY™ (Paltusotine) Net Product Revenue of $10.3 Million for First-Quarter 2026, with 232 Enrollment Forms in the First Quarter Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today reported financial results for the first quarter ended March 31, 2026. "We are extremely pleased with the significant impact that Palsonify is making across the community. This is illustrated by the strong adoption of Pa
- SECSEC Form DEF 14A filed by Crinetics Pharmaceuticals Inc.DEF 14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- SECSEC Form DEFA14A filed by Crinetics Pharmaceuticals Inc.DEFA14A - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRCrinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in AdultsPALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly
- PRNeutrolis Appoints Caren Deardorf as Chief Business & Strategy OfficerMs. Deardorf is an experienced biopharma leader who will lead business development and corporate and commercial strategy as Neutrolis advances NTR-1011 into autoimmune diseases following positive Phase 1a results CAMBRIDGE, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Neutrolis Inc. a clinical-stage biotechnology company focused on targeting Neutrophil Extracellular Traps (NETs) for the treatment of autoimmune and inflammatory diseases, today announced the appointment of Caren Deardorf as Chief Business & Strategy Officer (CBSO). Ms. Deardorf will lead corporate and pipeline strategy, business development, and early commercial strategy as the company advances its clinical pipeline. Ms. Dear
- INSIDERSEC Form 4 filed by Knight Jeff E.4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECCrinetics Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- PRCrinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026SAN DIEGO, April 08, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Thursday, May 7 at 4:30 p.m. ET Domestic:1 833-461-5787International:1 585-542-9983Meeting ID:173777518 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link (HERE) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that par
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Crinetics Pharmaceuticals Inc.SCHEDULE 13G/A - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- PRCrinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in AcromegalySAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced the submission of a Marketing Authorization Application (MAA) to Brazil's National Health Surveillance Agency (ANVISA) for PALSONIFY™ (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the proposed treatment of acromegaly in adults. "The submission of our MAA for Palsonify in Brazil represents another important global milestone for this important therapy," said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. "Once-daily, oral Palsonify is redefining the treatment paradigm as the next generati
- SECSEC Form 8-K filed by Crinetics Pharmaceuticals Inc.8-K - Crinetics Pharmaceuticals, Inc. (0001658247) (Filer)
- INSIDERSEC Form 4 filed by Crinetics Pharmaceuticals Inc.4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERSEC Form 4 filed by Knight Jeff E.4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- INSIDERSEC Form 4 filed by Struthers Richard Scott4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
- SECSEC Form 144 filed by Crinetics Pharmaceuticals Inc.144 - Crinetics Pharmaceuticals, Inc. (0001658247) (Subject)
- INSIDERDirector Vivaldi Coelho Rogerio sold $180,761 worth of shares (5,000 units at $36.15), decreasing direct ownership by 23% to 16,300 units (SEC Form 4)4 - Crinetics Pharmaceuticals, Inc. (0001658247) (Issuer)
CRNX FAQ
7 questionsWhat does Crinetics Pharmaceuticals Inc. do?
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist that has completed phase II clinical trial for the treatment of acromegaly, as well as completed phase 1 clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide...Where does CRNX stock trade?
Crinetics Pharmaceuticals Inc. (CRNX) is listed on NASDAQ.What sector and industry is CRNX in?
Crinetics Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Crinetics Pharmaceuticals Inc. go public?
Crinetics Pharmaceuticals Inc. (CRNX) completed its IPO in 2018.What are analysts saying about CRNX?
Crinetics Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Goldman: Buy on 2026-01-12. Recent price targets cluster around $3600.00.What companies are similar to CRNX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CRNX side-by-side with any of them on Quantisnow.How can I track CRNX on Quantisnow?
Quantisnow aggregates Crinetics Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CRNX to receive live email and push alerts on every new disclosure.